Please login to the form below

Not currently logged in
Email:
Password:

ovarian cancer

This page shows the latest ovarian cancer news and features for those working in and with pharma, biotech and healthcare.

AZ showcases data for next-generation PARP inhibitor AZD5305

AZ showcases data for next-generation PARP inhibitor AZD5305

candidate. “Our data at AACR reflect a robust early-stage pipeline, poised to deliver life-changing medicines to patients living with cancer. ... The ongoing study found that Zn-c3 generated five partial responses (PR), with two confirmed PRs in

Latest news

More from news
Approximately 37 fully matching, plus 181 partially matching documents found.

Latest Intelligence

  • After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream After years of potential, cell and gene therapy is ready for the pharmaceutical mainstream

    These T cells are then injected back into the bloodstream with the aim of targeting and killing cancer cells. ... Currently the company is conducting a phase 1 trial for advanced ovarian cancer in a dose escalation trial that will treat four separate

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    That includes potential new approvals for PARP inhibitor Lynparza in prostate and pancreatic cancer to extend its existing use in ovarian and breast cancer. ... in July 2019, which involved 22 plaintiffs who alleged using J&J talc caused them to develop

  • Case study: Ovarian Cancer Action (OCA) Case study: Ovarian Cancer Action (OCA)

    Every rose had a tag with the symptoms of ovarian cancer, Ovarian Cancer Action’s url and #WOCD. ... The charity also lobbied politicians across the UK to support World Ovarian Cancer Day.

  • Leading AstraZeneca’s return to growth in Europe Leading AstraZeneca’s return to growth in Europe

    Reic said the adoption of diagnostics into standard clinical practice has been one of the biggest challenges in Lynparza’s first indication, ovarian cancer – but this must now be replicated in ... First we had ovarian cancer, then breast cancer, and

  • AstraZeneca’s oncology renaissance AstraZeneca’s oncology renaissance

    Eight years on, three new oncology drugs are proving to be the driving force for the new AstraZeneca: small molecule, targeted lung cancer drug Tagrisso (osimertinib) and ovarian cancer treatment Lynparza ... People who have BRCA gene mutations have an

More from intelligence
Approximately 0 fully matching, plus 18 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 7 partially matching documents found.

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Fishawack Health

Fishawack Health is the leading global commercialization partner for the modern life science era. Established in 2001 and headquartered in...

Latest intelligence

DATA shutterstock_1818502577-640.jpg
Empowering patients empowers results
Patient-centricity is key when it comes to creating a more flexible, efficient and modern process for clinical trials...
Don’t limit diversity to just representation in clinical trials
What is the power of diversity in the healthcare environment? Can it make clinical trials more inclusive?...
Oh no… not more training
Paul Hutchings, founder of fox&cat, discusses ways to help your team manage pressure in a more human, pressure-centric and engaging way...

Infographics